[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
3. Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A: Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer; 2008;8:252
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
  • BACKGROUND: Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes.
  • The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer.
  • METHODS: The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres.
  • Patients with recurrent ovarian cancer with > 6 months of platinum free interval were considered eligible.
  • RESULTS: Twenty patients with mucinous histotype and 388 patients with other histotypes were analyzed.
  • At baseline, mucinous tumours differed from the others for an higher number of patients with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025).
  • At time of recurrence, a statistically significant difference was found in performance status (worse in mucinous, p = 0.024).
  • About 20% of patients underwent secondary cytoreduction in both groups, but a lower number of patients were optimally debulked in the mucinous group (p = 0.03).
  • Patients with mucinous cancer received more frequently single agent platinum than platinum based-combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a response rate lower than in non-mucinous group (36.4% vs 62.6%, respectively, p = 0.04).
  • Median time to progression and overall survival were worse for mucinous ovarian cancer.
  • Finally, mucinous cancer received a lower number of chemotherapy lines (p = 0.0023).
  • CONCLUSION: This analysis shows that platinum sensitive mucinous ovarian cancer has a poor response to chemotherapy.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):160-6 [14751152.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):33-5 [8261457.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1545-51 [8622070.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1581-6 [9118042.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):436-41 [15863142.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3501-5 [16101169.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii7-viii12 [16239238.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):171-5 [16546243.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4699-707 [16966687.001]
  • [Cites] Oncology. 2006;71(5-6):320-6 [17878745.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2984-97 [11595686.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):399-403 [11855877.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • (PMID = 18761742.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2538544
  •  go-up   go-down


Advertisement
4. Sasaki H, Ohara N, Minamikawa T, Umeda M, Komori T, Kojima N, Takemura N, Morita H, Sugihara R, Enoki E, Itoh T: Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). Kobe J Med Sci; 2008;54(3):E174-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report).
  • Most metastatic tumors have the propensity for involving the mandible rather than the oral soft tissues.
  • Herein, we describe an unusual case of ovarian mucinous cystadenocarcinoma that metastasized to the mandibular gingiva as an initial manifestation.
  • There is little information regarding metastatic ovarian cancer to the oral cavity.
  • A patient was a 54-year-old woman who developed the paresthesia and swelling of the right mandible after tooth extraction.
  • A biopsy taken from the gingiva showed mucinous adenocarcinoma, indicating the gingival metastasis of undiscovered primary cancer.
  • A positron emission tomography and computed tomography using 18F-fluorodeoxyglucose depicted an ovarian tumor with multiple pelvic and paraaortic lymph node swellings.
  • A magnetic resonance imaging (MRI) clearly demonstrated the presence of an ovarian cancer.
  • Based on the imaging studies, the diagnosis of the gingival metastasis of an ovarian cancer was suspected.
  • The histology of surgical specimen confirmed the gingival metastasis of ovarian mucinous adenocarcinoma.
  • She has been treated with adjuvant chemotherapy consisting of paclitaxel and carboplatin.
  • This case emphasizes that although rare, metastatic ovarian cancer to the gingiva should be included in the differential diagnosis of tumors in the oral cavity.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Gingival Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biopsy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Positron-Emission Tomography. Radiography, Panoramic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246966.001).
  • [ISSN] 1883-0498
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. El-Safadi S, Stahl U, Tinneberg HR, Hackethal A, Muenstedt K: Primary signet ring cell mucinous ovarian carcinoma: a case report and literature review. Case Rep Oncol; 2010 Sep;3(3):451-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet ring cell mucinous ovarian carcinoma: a case report and literature review.
  • A 24-year-old female patient presented with an extremely rare primary signet cell carcinoma of the right ovary 1 year after surgery for a mucinous borderline tumour of the left ovary.
  • Surgery was followed by 6 courses of paclitaxel/carboplatinum chemotherapy.
  • After an initial response, the patient again developed increasing ascites.
  • After 5 months, ascites developed in the retroperitoneum so that the chemotherapy had to be changed.
  • In spite of a positive response with the new chemotherapy, the patient died of a very rare pulmonary complication after 1 month within 2 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 May;77(2):323-6 [10785488.001]
  • [Cites] Ultrastruct Pathol. 1995 Sep-Oct;19(5):401-19 [7483017.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):323-8 [11603214.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):45-51 [14668550.001]
  • [Cites] Anticancer Drugs. 2007 Oct;18(9):1093-101 [17704660.001]
  • [Cites] Cancer. 1976 Jul;38(1):166-72 [181127.001]
  • [Cites] Chest. 2008 Feb;133(2):528-38 [18252919.001]
  • [Cites] Pathol Oncol Res. 2008 Sep;14(3):333-6 [18758997.001]
  • [Cites] Clin Transl Oncol. 2008 Sep;10(9):583-6 [18796376.001]
  • [Cites] Int J Colorectal Dis. 2010 Feb;25(2):233-8 [19705132.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(4):333-6 [8389502.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jan-Feb;13(1):90-3 [12631228.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):165-72 [17413984.001]
  • [Cites] Int J Surg Pathol. 2008 Apr;16(2):180-4 [18417676.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1373-9 [18670351.001]
  • [Cites] Med Mol Morphol. 2008 Sep;41(3):165-70 [18807143.001]
  • [Cites] Clin Transl Oncol. 2009 Nov;11(11):753-9 [19917539.001]
  • [Cites] Cancer. 1968 Dec;22(6):1199-207 [4303165.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):557-68 [11342766.001]
  • (PMID = 21611142.001).
  • [ISSN] 1662-6575
  • [Journal-full-title] Case reports in oncology
  • [ISO-abbreviation] Case Rep Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3100266
  • [Keywords] NOTNLM ; Krukenberg's tumour / Mucinous carcinoma / Ovarian cancer / Pseudomyxoma peritonei / Pulmonary complication / Signet ring cell carcinoma
  •  go-up   go-down


6. Milenković V, Sparić R, Dokić M, Petković S, Atanacković J: [Ovarian cancer after in vitro fertilization]. Srp Arh Celok Lek; 2004 Sep-Oct;132(9-10):331-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cancer after in vitro fertilization].
  • There is serious concern about cancer risk in women undergoing ovarian stimulation treatment for infertility and longterm safety of these procedures.
  • Association between fertility drugs and ovarian cancer is still controversial.
  • A 30-year-old woman was referred to our institution with the initial diagnosis of an adnexal tumor after in vitro fertilization.
  • Her history revealed adnexectomy for mucinous cystadenofibroma of the left ovary eight years ago, and cystectomy due to cystadenoma of the right ovary three years ago.
  • Broad spectrum antibiotic treatment was initiated.
  • Pathological diagnosis was mucinous ovarian adenocarcinoma.
  • After the surgery, chemotherapy was applied.
  • There is an urgent need for clear interpretation of the association between fertility drugs and subsequent higher ovarian cancer risk.
  • Lacking conclusive evidence, an increased risk of ovarian cancer has been reported and more recently disputed.
  • Higher ovarian cancer risk may be serious and even life-threatening complication for women undergoing ovarian stimulation.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / chemically induced. Fertility Agents, Female / adverse effects. Fertilization in Vitro / adverse effects. Ovarian Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794056.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  • [Chemical-registry-number] 0 / Fertility Agents, Female
  •  go-up   go-down


7. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Computed tomography showed an 18 x 16 cm right pelvic tumor, with both cystic and solid components, ascites and bilateral massive pleural effusion.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • CONCLUSION: The coexistence of primary neoplasms in the ovary and cervix is rare.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Necrosis. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


8. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol; 2009 Jun;113(3):331-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
  • OBJECTIVE: We conducted the present study to clarify the clinicopathological characteristics of mucinous adenocarcinoma.
  • METHODS: Two hundred twenty-five patients were diagnosed with mucinous adenocarcinoma at individual institutes and underwent primary treatment between 1998 and 2003.
  • Of 189 patients undergoing central pathological review, 64 patients (33.9%) were diagnosed with mucinous invasive adenocarcinoma, 45 mucinous intraepithelial carcinoma, and 42 mucinous tumor of borderline malignancy.
  • Twenty-five patients were diagnosed with other histological subtypes, including 8 endometrioid adenocarcinoma, 5 clear cell carcinoma, 3 serous adenocarcinoma, and 4 mixed type.
  • There were 13 cases of metastatic mucinous adenocarcinoma, including 7 pseudomyxoma peritonei.
  • Four hundred thirty-three patients with serous adenocarcinoma were used as controls.
  • RESULTS: Forty-five patients with mucinous invasive carcinoma were in FIGO I-II stages and 19 in III-IV stages.
  • There was no difference in the outcome between mucinous invasive adenocarcinoma and serous adenocarcinoma in I-II stage patients and III-IV stage patients with optimal operation.
  • In contrast, patients with mucinous invasive adenocarcinoma receiving suboptimal operation showed a significantly worse prognosis (survival rate: 27.8% vs. 61.5%).
  • The response rate to chemotherapy for mucinous invasive adenocarcinoma was significantly lower than for serous adenocarcinoma (12.5% vs. 67.7%).
  • CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult.
  • Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients.
  • A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Case-Control Studies. Female. Humans. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275957.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Bing Z, Adegboyega PA: Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):104-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors.
  • The authors report the first case of ovarian mucinous adenocarcinoma with metastasis from a synchronous small cell neuroendocrine carcinoma of the lung.
  • Bronchial brushing as well as transbronchial fine-needle aspiration was diagnostic of small cell carcinoma.
  • The patient received 3 cycles of chemotherapy with carboplatin and subsequently underwent a supracervical hysterectomy and bilateral salpingo-oophorectomy.
  • A large, multiloculated cystic mass was found arising from the right ovary.
  • Microscopic examination disclosed a mucinous neoplasm with both mucinous cystadenoma and mucinous papillary adenocarcinoma components.
  • A microscopic focus of cells with "atypical" cytomorphologic features was detected within the mucinous neoplasm.
  • Immunohistochemistry showed that group of cells to be positive for thyroid transcription factor 1 and chromogranin, confirming them to be metastasis from the pulmonary small cell neuroendocrine carcinoma.
  • This case, in addition to being the first reported case of such metastasis, also highlights the diagnostic utility of immunohistochemistry as a reliable and very useful ancillary technique for the diagnosis of neoplasms with unusual clinical and/or histomorphologic presentations.

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722802.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 1.11.1.- / Peroxidases
  •  go-up   go-down


10. Papathanasiou K, Tolikas A, Dovas D, Kostopoulou E, Fragkedakis N, Tzafettas J: Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1191-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology.
  • A case of a mucinous adenocarcinoma of the ovary with a synchronous endometroid tumor of the endometrium with focal features of undifferentiated carcinoma and deep myometrial invasion is reported.
  • A review of the literature revealed that our case is interesting in view of the fact that simultaneous presentation of primary ovarian and endometrial neoplasms is rare and usually related to low-stage ovarian lesions and well-differentiated and superficial endometrial carcinomas in contrast to our case with the focal features of undifferentiated carcinoma and the deep myometrial invasion.
  • The prognosis in most of the cases is surprisingly good even after total abdominal hysterectomy and bilateral oophorectomy alone without adjuvant chemotherapy or irradiation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kolosov AE, Novichkov EV: [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma]. Arkh Patol; 2003 Sep-Oct;65(5):29-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].
  • The aim of the study was to investigate the prognostic value of morphometrical features and expression of receptors to progesterone in malignant epithelial ovarian tumours.
  • Surgical biopsy materials of 92 patients with serous and mucinous ovarian cancer were investigated.
  • Tissues stained by hematoxilin and eosin were studied.
  • It was found that cytomorphometrical features vary in ovarian cancer with different histological structures and the level of differentiation of tumour, and can be used as prognostic factors.
  • We revealed correlation between cytomorphometric factors (carcinoma cell area, total nuclear area, roundness of cell) and risk of recurrences and metastatic spread.
  • In this group of patients 3-year survival reached almost 100% indicating the efficiency of hormonotherapy and chemotherapy.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14664145.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Receptors, Progesterone
  •  go-up   go-down


12. Kim SM, Choi HS, Byun JS, Kim YH, Kim KS, Rim SY, Kim HR, Nam JH, Choi YD: Mucinous adenocarcinoma and strumal carcinoid tumor arising in one mature cystic teratoma of the ovary with synchronous cervical cancer. J Obstet Gynaecol Res; 2003 Feb;29(1):28-32
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma and strumal carcinoid tumor arising in one mature cystic teratoma of the ovary with synchronous cervical cancer.
  • While any of the constituent tissues of a teratoma has the potential to undergo malignant transformation, squamous cell carcinoma is the most commonly associated cancer.
  • We present an unusual case of a postmenopausal woman with synchronous mucinous adenocarcinoma and strumal carcinoid tumor from one of two ovarian mature cystic teratomas (one in each ovary) with synchronous cervical cancer.
  • We suggest that malignant transformation of mature cystic teratoma and synchronous cervical cancer be treated by hysterectomy, chemotherapy, and radiotherapy.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoid Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis. Struma Ovarii / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Teratoma / complications. Teratoma / diagnosis. Teratoma / pathology


13. Swiatkowska-Freund M, Preis K, Emerich J: [Appendiceal mucinous carcinoma]. Ginekol Pol; 2000 Oct;71(10):1277-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Appendiceal mucinous carcinoma].
  • Appendiceal carcinoma is very rare.
  • Preoperative diagnosis of this kind of neoplasm is difficult.
  • Even at operation in under half of cases this diagnosis is considered.
  • We present a case of a woman admitted to the hospital with diagnosis of adnexal tumor of the right ovary.
  • The diagnosis of adnexal mass was confirmed by ultrasound examination.
  • She received chemotherapy with 5-FU.
  • After 9 months computed tomography revealed no changes in abdomen.
  • Diagnosis of pelvic masses when they do not origin of adnexis is usually very difficult.
  • In many cases proper diagnosis is made only during laparotomy.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Intestinal Neoplasms / secondary. Intestinal Neoplasms / therapy. Laparotomy. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143937.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Martínez-Román S, Ramirez PT, Oh J, Viciedo MG, MacApinlac HA: Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol; 2005 Mar;96(3):888-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma.
  • BACKGROUND: The role of combined positron emission tomography and computed tomography (PET-CT) in the diagnosis of recurrent ovarian mucinous adenocarcinoma is uncertain because of previous reports that PET has limited sensitivity in the detection of mucinous neoplasms.
  • The diagnosis was FIGO stage IIIC well-differentiated ovarian mucinous adenocarcinoma.
  • Four months after completing chemotherapy, the patient was noted to have an elevated serum CA125 level (72 U/mL), being otherwise asymptomatic.
  • CONCLUSION: PET-CT may identify clinically occult recurrent ovarian mucinous adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / radionuclide imaging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721446.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Kunz J, Makek M: [Primary adenocarcinoma of the appendix as differential diagnosis of advanced ovarian carcinoma]. Praxis (Bern 1994); 2006 Aug 16;95(33):1217-25
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the appendix as differential diagnosis of advanced ovarian carcinoma].
  • [Transliterated title] Das primäre Adenokarzinom der Appendix als Differentialdiagnose des fortgeschrittenen Ovarialkarzinoms.
  • Metastatic mucinous adenocarcinomas of the appendix are only reported as case histories.
  • In clinical terms, the tumours usually manifest themselves as acute appendicitis, as ruptured appendicitis, as a tumour in the right lower abdominal quadrant or as a pelvic tumour, which are generally mistaken for an ovarian tumour with the same sonographic image.
  • Advanced primary adenocarcinomas of the appendix with ovarian metastases cannot be distinguished intraoperatively from a FIGO III ovarian carcinoma.
  • The pathologist makes the definitive diagnosis.
  • Surgical therapy of the isolated primary appendiceal carcinoma consists of a hemicolectomy--an appendectomy in favourable cases--and, in the case of a metastasised carcinoma, according to the guidelines for an advanced ovarian or colon carcinoma.
  • The effect of chemotherapy is insufficiently documented.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Appendix / pathology. Appendix / surgery. Diagnosis, Differential. Female. Humans. Hysterectomy, Vaginal. Middle Aged. Omentum / pathology. Omentum / surgery. Ovary / pathology. Ovary / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Peritoneum / pathology. Peritoneum / surgery. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Postoperative Complications / surgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939122.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Ishioka S, Hayashi T, Endo T, Baba T, Honma H, Saito T: Advanced epithelial ovarian carcinoma during pregnancy. Int J Clin Oncol; 2007 Oct;12(5):375-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced epithelial ovarian carcinoma during pregnancy.
  • We report a rare case of advanced ovarian mucinous adenocarcinoma in a pregnant woman.
  • A 28-year-old pregnant Japanese woman was diagnosed with an ovarian tumor 8 cm in diameter at a local hospital.
  • She was sent to a private hospital at 25 weeks of gestation because of the growing ovarian tumor.
  • Advanced ovarian carcinoma with widespread intraabdominal dissemination was detected by laparotomy at the hospital and she was referred to our hospital for further management.
  • The pathological diagnosis of the tumor was mucinous cystadenocarcinoma grade 2.
  • Although chemotherapy was not effective for her and she died of the disease 4 months after the surgery, her baby grew well and weighed 3750 g 3 months after delivery.
  • For the treatment of such patients, we believe we should choose operative therapy as early as possible after the maturation of the fetus, although there are several reports of successful treatment with the administration of chemotherapy during pregnancy.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Dec;27(6):686-98 [11130476.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jun 15;149(4):384-7 [6731515.001]
  • [Cites] Am J Obstet Gynecol. 1989 Mar;160(3):563-6 [2929674.001]
  • [Cites] Acta Paediatr. 2004 Jul;93(7):945-53 [15303811.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):600-4 [15297214.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):78-80 [2026364.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1120-3 [16343192.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):8-15 [16445603.001]
  • [Cites] J Nippon Med Sch. 2002 Feb;69(1):39-42 [11847508.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):545-7 [2304734.001]
  • (PMID = 17929120.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Jeremic K, Gojnic M, Milenković V, Petković S, Stojnić J, Lazović G, Berisavac M, Jeremić J: Treatment for infertility and risk of invasive epithelial ovarian cancer--a case report. Clin Exp Obstet Gynecol; 2006;33(3):190-1
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for infertility and risk of invasive epithelial ovarian cancer--a case report.
  • A 30-year-old women was admitted to the Institute of Gynecology and Obstetrics, Clinical Center of Serbia in April 2004 with the following diagnosis: adnexal mass soon after in vitro fertilization.
  • Her history revealed salpingo-oophorectomy for mucinous cystadenofibroma of the left ovary eight years before and cystectomy of the right ovary three years before.
  • After the antibiotic treatment, laparatomy was performed and a multilocular right adnexal tumor was found.
  • The right salpingo-oophorectomy was performed and pathological diagnosis was mucinous ovarian adenocarcinoma.
  • Two weeks later, radical surgery was carried out and chemotherapy was applied.
  • There is an urgent need for clear interpretation of the link between ovarian stimulation and ovarian cancer.
  • An association between ovarian stimulation treatment and ovarian cancer has still not been completely proven.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Gonadotropins / adverse effects. Humans. Infertility, Female / therapy. Neoplasm Invasiveness. Ovariectomy. Ovulation Induction / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089588.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gonadotropins
  •  go-up   go-down


19. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, Shepherd JH, Ind T, Bridges J, Harrington K, Kaye SB, Gore ME: Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol; 2004 Mar 15;22(6):1040-4
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.
  • PURPOSE: Invasive mucinous carcinoma of the ovary (mucinous epithelial ovarian cancer [mEOC]) is a histologic subgroup of epithelial ovarian cancer (EOC).
  • Chemotherapy for mEOC is chosen according to guidelines established for EOC.
  • PATIENTS AND METHODS: Women with advanced mEOC (International Federation of Gynecology and Obstetrics stage III or IV) who underwent first-line platinum-based chemotherapy were compared with women with other histologic subtypes of EOC in a case-controlled study.
  • The odds ratio for complete or partial response to chemotherapy for mEOC was 0.19 (95% CI, 0.06 to 0.66; P=.009) compared with other histologic subtypes of EOC.
  • CONCLUSION: Patients with advanced mEOC have a poorer response to platinum-based first-line chemotherapy compared with patients with other histologic subtypes of EOC, and their survival is worse.
  • Specific alternative therapeutic approaches should be sought for this group of patients, perhaps involving fluorouracil-based chemotherapy.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Platinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Retrospective Studies. Survival Analysis


20. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W: The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res; 2010;18(7):343-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
  • The role of estrogens in ovarian carcinogenesis and progression of ovarian cancer is unclear.
  • Cytochrome P450 is involved in estrogen metabolism, and polymorphisms have been associated with functional changes and risk for ovarian cancer.
  • In this study, we investigated the impact of the CYP1A1 Ile462Val polymorphism upon tumor risk and disease progression in ovarian cancer patients.
  • One hundred and eleven ovarian cancer patients who had been treated at the University Hospital of Essen between 1999 and 2007 and 119 age-matched healthy female controls were enrolled in this study.
  • The distribution of genotypes was statistically significant different between ovarian cancer patients and healthy controls.
  • We observed a significant association of the Ile allele with ovarian cancer (OR 2.6, 95% CI 1.5-4.7, p = 0.001).
  • Clinical parameters such as overall survival, FIGO stage, grading, and age at diagnosis did not differ significantly.
  • We observed a statistically significant association between the 462Val allele and platinum resistance, which was defined as a time interval < 6 months to disease progression after administration of a platinum-based primary chemotherapy (OR 5.9, 95% CI 1.5-23.2, p = 0.005).
  • We observed a significant association between the presence of the 462Ile allele with ovarian cancer.
  • While there is uncertainty about the potential involvement of CYP1A1 in the metabolism of platinum-containing agents, our findings suggest an association between the 462Val allele and the development of platinum resistance in ovarian tumors.
  • If confirmed in a larger, independent collective, our findings would have important relevance with respect to the clinical consequences for the primary chemotherapy of ovarian cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytochrome P-450 CYP1A1 / genetics. Drug Resistance, Neoplasm / genetics. Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Female. Genotype. Humans. Middle Aged. Ovary / metabolism. Ovary / pathology. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377136.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


21. Salomon LJ, Lhommé C, Pautier P, Duvillard P, Morice P: Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil Steril; 2006 May;85(5):1510.e1-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of simple cystectomy in patients with unilateral mucinous borderline tumors.
  • OBJECTIVE: To report on ovarian carcinoma development after cystectomy for a borderline mucinous ovarian tumor.
  • PATIENT(S): One patient who developed recurrence in the form of an invasive ovarian carcinoma after simple cystectomy for a borderline mucinous ovarian tumor.
  • Histological examination revealed a borderline mucinous ovarian tumor.
  • No additional treatment was prescribed.
  • Two years later, the patient relapsed with a malignant mucinous ovarian carcinoma.
  • She underwent surgical resection and staging, including hysterectomy, bilateral adnexectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, and platinum-based chemotherapy.
  • CONCLUSION(S): Recurrence in the form of invasive ovarian carcinoma may occur in the same ovary after cystectomy in cases of borderline mucinous ovarian tumor.
  • Such treatment enables preservation of reproductive potential and reduces the risk of developing invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Cystectomy / adverse effects. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / prevention & control. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647380.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Malhotra N, Sumana G, Singh A, Deka D, Mittal S: Rupture of a malignant ovarian tumor in pregnancy presenting as acute abdomen. Arch Gynecol Obstet; 2010 May;281(5):959-61
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rupture of a malignant ovarian tumor in pregnancy presenting as acute abdomen.
  • INTRODUCTION: Ovarian neoplasms in pregnancy are usually asymptomatic rarely leading onto complications.
  • A 30-year-old G2 P1+0+0+1 was referred at 30 weeks of pregnancy with an ultrasound diagnosis of a large multicystic ovarian cyst with no solid areas, ascites or evidence of metastasis.
  • Clinical examination revealed a relaxed uterus and ultrasound was suggestive of rupture of the ovarian cyst.
  • Exploratory laparotomy revealed a ruptured left mucinous ovarian cyst with no evidence of solid areas or metastasis.
  • Histopathology revealed stage-1c mucinous cyst adenocarcinoma of left ovary.
  • She is now receiving postoperative chemotherapy.
  • CONCLUSION: This is the first reported case of a ruptured malignant ovarian tumor in pregnancy.
  • Torsion or rupture of ovarian masses is an important differential diagnosis of abdominal or pelvic pain during pregnancy.
  • [MeSH-major] Abdomen, Acute / etiology. Adenocarcinoma, Mucinous / complications. Ovarian Neoplasms / complications. Ovary / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949808.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Spörri S, Chopra V, Egger N, Hawkins HK, Motamedi M, Dreher E, Schneider H: Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells in vitro. J Photochem Photobiol B; 2001 Nov 1;64(1):8-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells in vitro.
  • Results are reported on the cellular effects and the sensitivity of cultured tumor epithelial cells (TEC) derived from human ovarian cystadenocarcinoma and human umbilical vein-derived endothelial cells (HUVEC) to exogenous 5-aminolaevulinic acid (ALA) and ALA-induced photodynamic therapy (PDT).
  • ALA-induced protoporphyrin IX (PpIX) accumulation in TEC was associated with a concentration and time-dependent significant decrease in mitochondrial activity, increase in cell membrane permeability, and dark toxicity.
  • These results indicate a potential clinical value for the use of ALA-mediated PDT to treat minimal residual disease in mucinous ovarian carcinoma.
  • [MeSH-major] Aminolevulinic Acid / toxicity. Endothelium, Vascular / drug effects. Ovarian Neoplasms / pathology. Photosensitizing Agents / toxicity
  • [MeSH-minor] Cell Membrane Permeability / drug effects. Cell Survival / drug effects. Cells, Cultured. Cystadenocarcinoma, Mucinous / pathology. Dose-Response Relationship, Drug. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Female. Humans. Kinetics. Light. Mitochondria / drug effects. Mitochondria / metabolism. Protoporphyrins / metabolism. Reactive Oxygen Species / metabolism. Tumor Cells, Cultured. Umbilical Veins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705725.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / Reactive Oxygen Species; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


24. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


25. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR: Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother; 2004 Jan;58(1):24-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
  • CA 125 is the most reliable serum marker for ovarian carcinoma.
  • Whereas its role in the screening of the malignancy is controversial, serum CA 125 assay is very useful for both the differential diagnosis of ovarian masses, particularly in postmenopause, and the monitoring of the response to chemotherapy and follow-up of patients with histologically proven ovarian carcinoma.
  • Tumor-associated antigens other than CA 125, such as CA 19.9, CA 15.3 and TAG.72, firstly identified in gastro-intestinal or breast malignancies, have been detected also in tissue and serum samples from patients with ovarian carcinoma.
  • In particular CA19.9 offers the advantage of high sensitivity for mucinous histotype, which often fails to express CA 125.
  • Serum CA 125 correlates with the clinical course of disease better than the other antigens, and in patients with positive CA 125 assay at diagnosis the concomitant evaluation of CA 19.9 or CA 72.4 or CA 15.3 does not offer any additional benefit for monitoring ovarian carcinoma.
  • Serum alphaFP and betaHCG are very useful in the preoperative evaluation and management of nondysgerminomatous ovarian germ cell tumors, whereas elevated serum inhibin levels can be detected in patients with granulosa cell tumors of the ovary.
  • As for endometrial carcinoma, preoperative serum CA 125 levels correlate with stage, depth of myometrial invasion, histologic grade, cervical invasion, peritoneal cytology, lymph node status and clinical outcome.
  • Moreover, serial CA 125 assay is a good indicator of disease activity and a useful biochemical tool for post-treatment surveillance of patients with endometrial carcinoma.
  • SCC is the most reliable serum marker for squamous cell cervical carcinoma, and in patients with this malignancy pretreatment SCC levels are related to tumor stage, tumor size, depth of cervical invasion, lymph-vascular space involvement, lymph node status and clinical outcome.
  • Serial SCC measurements parallel the response to radiotherapy and chemotherapy as well as the clinical course of disease after the completion of treatment.
  • Serum CYFRA 21.1 seems to be less sensitive than serum SCC for squamous cell cervical carcinoma.
  • Elevated CA 125 levels can be often detected in patients with cervical adenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Endometrial Neoplasms / therapy. Ovarian Neoplasms / blood. Ovarian Neoplasms / therapy. Uterine Cervical Neoplasms / blood. Uterine Cervical Neoplasms / therapy


26. Lee KR, Nucci MR: Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol; 2003 Jan;22(1):42-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis.
  • The epithelial cells of ovarian mucinous carcinomas may sometimes appear similar to those of gastrointestinal or endocervical mucinous carcinomas, but most are composed of cells that do not suggest any particular derivation.
  • We report four cases of mucinous ovarian carcinoma in which the cells were entirely or almost entirely endocervical-like.
  • Two patients had bilateral tumors confined to the ovaries at initial staging; both also had synchronous endometrial carcinomas of the mucinous type.
  • In one of the latter cases a mullerian (endocervical-like) mucinous borderline tumor (MMBT) of the opposite ovary had been removed 5 years earlier, and in this case and two other cases the ovarian carcinomas had foci resembling MMBT, suggesting that they may be an invasive counterpart to these tumors.
  • The epithelial cells were well differentiated with infrequent mitoses and most were tall with mucinous cytoplasm resembling normal endocervical glandular cells.
  • Endometriosis was present in residual ovarian tissue adjacent to four tumors in three patients and had marked epithelial proliferation in three.
  • All patients were treated postoperatively with chemotherapy and were without clinical recurrence with follow-up intervals of 8 months, 1.2 years, 2.9 years, and 3.8 years.
  • By immunohistochemical analysis the neoplastic epithelium was positive for estrogen and progesterone receptor proteins, vimentin, and cytokeratin 7, and negative or only focally positive for carcinoembryonic antigen and cytokeratin 20, a profile that differs from that of the usual mucinous ovarian carcinoma and is supportive of a mullerian derivation.
  • To better understand their clinicopathologic features and pathogenesis, this uncommon variant should be separated from the usual type in future studies of mucinous carcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometriosis / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12496697.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


27. Hopkins ML, Depetrillo AD, Le T, Fung MF: Pseudomyxoma peritonei: a case series and review of the literature. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):32-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a case series of patients with a diagnosis of PMP treated between January 1, 1995 and December 31, 2001.
  • The remaining patient underwent appendectomy, but it was not sufficiently sectioned for diagnosis.
  • Chemotherapy was given to patients in a non-uniform fashion.
  • Removal of mucinous tumors of the ovary should include appendectomy.
  • [MeSH-major] Adenocarcinoma / complications. Appendiceal Neoplasms / complications. Pseudomyxoma Peritonei / etiology. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Appendectomy. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Ontario / epidemiology. Referral and Consultation / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670294.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down






Advertisement